The European Union on Wednesday slapped a $475 million fine on U.S. biotech giant Illumina for buying out cancer-screening company Grail without the approval of the 27-nation bloc’s antitrust watchdog, the latest setback for the deal.
Source: washingtontimes.com
Please follow and like us:
